These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 23255089

  • 21. Evolution in endometrial cancer: evidence from an immunohistochemical study.
    Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen L, Moerman P, Vergote I, Salvesen H, Amant F.
    Int J Gynecol Cancer; 2011 Feb; 21(2):316-22. PubMed ID: 21734474
    [Abstract] [Full Text] [Related]

  • 22. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M, Zhao L, Shen D, Li X, Wang J, Wei L.
    Chin Med J (Engl); 2014 Feb; 127(8):1459-63. PubMed ID: 24762589
    [Abstract] [Full Text] [Related]

  • 23. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J, Xie L, Luo X, Yang B, Zhang H, Zhu Q, Chen X.
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [Abstract] [Full Text] [Related]

  • 24. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
    Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.
    J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
    [Abstract] [Full Text] [Related]

  • 25. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ.
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [Abstract] [Full Text] [Related]

  • 26. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
    Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S.
    Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
    [Abstract] [Full Text] [Related]

  • 27. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.
    Cancer; 2003 Dec 15; 98(12):2547-53. PubMed ID: 14669272
    [Abstract] [Full Text] [Related]

  • 28. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
    Cell Biol Int; 2008 Jun 15; 32(6):698-707. PubMed ID: 18296077
    [Abstract] [Full Text] [Related]

  • 29. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K.
    Anticancer Res; 2007 Jun 15; 27(4A):2027-33. PubMed ID: 17649817
    [Abstract] [Full Text] [Related]

  • 30. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V, Briët J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H.
    Gynecol Oncol; 2009 Mar 15; 112(3):537-42. PubMed ID: 19108875
    [Abstract] [Full Text] [Related]

  • 31. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J, Hutt E, Bosq J, Graham JD, Powell MA, Leblanc E, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ.
    Gynecol Oncol; 2015 Sep 15; 138(3):663-7. PubMed ID: 26142884
    [Abstract] [Full Text] [Related]

  • 32. Stromal Clues in Endometrial Carcinoma: Loss of Expression of β-Catenin, Epithelial-Mesenchymal Transition Regulators, and Estrogen-Progesterone Receptor.
    Senol S, Sayar I, Ceyran AB, Ibiloglu I, Akalin I, Firat U, Kosemetin D, Engin Zerk P, Aydin A.
    Int J Gynecol Pathol; 2016 May 15; 35(3):238-48. PubMed ID: 26367784
    [Abstract] [Full Text] [Related]

  • 33. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F, Simionescu C, Georgescu CV, Pirici E.
    Rom J Morphol Embryol; 2011 May 15; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [Abstract] [Full Text] [Related]

  • 34. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX, Zhang P, Ma F, Yuan P, Wang JY, Xu BH, Li Q.
    Zhonghua Zhong Liu Za Zhi; 2018 Jul 23; 40(7):506-511. PubMed ID: 30060358
    [Abstract] [Full Text] [Related]

  • 35. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint.
    Kamoi S, AlJuboury MI, Akin MR, Silverberg SG.
    Int J Gynecol Pathol; 2002 Jul 23; 21(3):217-23. PubMed ID: 12068166
    [Abstract] [Full Text] [Related]

  • 36. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL, Sharkey FE, Cruz AB, Kahlenberg MS.
    Cancer; 2005 Jun 01; 103(11):2252-60. PubMed ID: 15834928
    [Abstract] [Full Text] [Related]

  • 37. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.
    Breast J; 2005 Jun 01; 11(4):278-80. PubMed ID: 15982396
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
    Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D.
    Neuroendocrinology; 2011 Jun 01; 93(4):249-58. PubMed ID: 21487213
    [Abstract] [Full Text] [Related]

  • 39. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
    Ma XM, Han YW, Zhang J, Cui WJ, Wang X.
    Zhonghua Zhong Liu Za Zhi; 2013 May 01; 35(5):372-6. PubMed ID: 24054015
    [Abstract] [Full Text] [Related]

  • 40. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM, Al Hamad M.
    Breast Cancer Res; 2005 May 01; 7(5):R598-604. PubMed ID: 16168103
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.